Payment overview · 2025
General Payments
$659.55
44 reported records · 7 companies
Healthcare provider profile · identity verified
James Despard Bailey, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRIDGEPORT, WV · NPI 1912933995
Verified facts
What the public records show
CMS Open Payments records show James Despard Bailey, MD received $659.55 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $282.96 | 42.9% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.74 | 26.6% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.33 | 10.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.34 | 8.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.48 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.64 | 4.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.06 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $659.55 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $166.56 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $128.42 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $128.42 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $119.20 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $109.07 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $68.33 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.33 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.34 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.64 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $11.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 97 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 124 |
| Alprazolam | Alprazolam | 332 | 41 |
| Omeprazole | Omeprazole | 328 | 92 |
| Lisinopril | Lisinopril | 324 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 291 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 78 |
| Lorazepam | Lorazepam | 286 | 53 |
| Gabapentin | Gabapentin | 273 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 72 |
| Metformin Hcl | Metformin Hcl | 233 | 72 |
| Losartan Potassium | Losartan Potassium | 223 | 63 |
| Meloxicam | Meloxicam | 213 | 70 |
| Simvastatin | Simvastatin | 206 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 52 |
| Tramadol Hcl | Tramadol Hcl | 162 | 29 |
| Furosemide | Furosemide | 142 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 42 |
| Azithromycin | Azithromycin | 124 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 34 |
| Montelukast Sodium | Montelukast Sodium | 119 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 35 |
| Trazodone Hcl | Trazodone Hcl | 110 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 33 |
| Potassium Chloride | Potassium Chloride | 104 | 37 |
| Eliquis | Apixaban | 97 | 22 |
| Allopurinol | Allopurinol | 92 | 24 |
| Sertraline Hcl | Sertraline Hcl | 88 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 22 |
| Famotidine | Famotidine | 74 | 17 |
| Methylprednisolone | Methylprednisolone | 74 | 43 |
| Mounjaro | Tirzepatide | 74 | suppressed |
| Clonazepam | Clonazepam | 70 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 18 |
| Meclizine Hcl | Meclizine Hcl | 63 | 11 |
| Synthroid | Levothyroxine Sodium | 63 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 15 |
| Valsartan | Valsartan | 60 | 18 |
| Atenolol | Atenolol | 55 | 17 |
| Carvedilol | Carvedilol | 55 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 40 |
| Ezetimibe | Ezetimibe | 50 | 15 |
| Glipizide | Glipizide | 50 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 16 |
| Spironolactone | Spironolactone | 50 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 16 |
| Diazepam | Diazepam | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 11 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Ozempic | Semaglutide | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | 11 |
| Topiramate | Topiramate | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Nystatin | Nystatin | 31 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 24 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 13 |
| Prednisone | Prednisone | 19 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $659.55 · 44 records | Novo Nordisk Inc | ELIQUIS, EVENITY, KRYSTEXXA, Kerendia, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error